• Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort

  NCT06762002

  RecruitingObservationalUpdated Sep 8, 2025
• Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions

  NCT06235580

  RecruitingObservationalUpdated Dec 19, 2025
• Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases

  NCT00341679

  CompletedObservationalUpdated Aug 24, 2026
• Novel Genetic Disorders of the Immune System

  NCT02257892

  RecruitingObservationalUpdated Jul 28, 2026
• Genetic and Immunologic Characterization of IEI

  NCT05803356

  CompletedObservationalUpdated Apr 7, 2023
• The Interplay Between Inborn Error of Immunity and Blood Disorders: Unravelling Immune Defects Behind Common Haematological Diseases

  NCT06857604

  RecruitingInterventionalNot ApplicableUpdated Mar 4, 2025

ClinicalTrials.gov ID

NCT07040774

Lead Sponsor

Imagine InstituteOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

500Estimated

Last Update Posted

May 13, 2026Actual

Start Date

Oct 1, 2025Actual

Primary Completion Date

Oct 2045Estimated

Completion Date

Oct 2045Estimated

Official Title

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Brief Summary

Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.

Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.

In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.

The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.

The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.

• Genetic Disease
• Immune Dysfunction
• Neurological Diseases or Conditions
• Autoimmune Diseases

Ages Eligible for Study

Child (0-17)Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Genetically confirmed patient with type I interferonopathy
• Patient affiliated to a social security scheme or beneficiary of such a scheme.

Exclusion Criteria:

- Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.

Observational Model

Cohort

Time Perspective

Cross-Sectional

Lead Sponsor

Imagine InstituteOTHER

A.mirguet@chru-nancy.fr